Autosomal dominant polycystic kidney disease: Pathophysiology and treatment

QJM: An International Journal of Medicine

Volumn 100, Issue 1, 2007, Pages 1-9

  Rapoport, Jayson ^a,b  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MOZAVAPTAN; MYC PROTEIN; POLYCYSTIN 1; POLYCYSTIN 2; RAPAMYCIN; SIMVASTATIN; SOMATOSTATIN; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; ANTISENSE THERAPY; APICAL MEMBRANE; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; CELL GROWTH; CHROMOSOME 16; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ELIMINATION; DYSLIPIDEMIA; ENZYME INHIBITION; GENE MUTATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOVOLEMIA; KIDNEY DYSFUNCTION; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; META ANALYSIS; NONHUMAN; ONCOGENE C MYC; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SECRETION; SYSTEMATIC REVIEW;

EID: 33845884078     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl129     Document Type: Review

References (78)

1. Verani RR, Silva FG. Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: A histochemical study. Mod Pathol 1988; 1:457-63.
2. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66:964-73.
3. Zeier M, Fehrenbach P, Gebertyh S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42:1259-65.
4. Bello-Reuss E, Holubec K, Rajaraman S. Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int 2001; 60:37-45.
5. Wilson PD, Polycystic Kidney Disease. N Engl J Med 2004; 350:151-64.
6. Grantham JJ. Fluid secretion, cellular proliferation, and the pathogenesis of renal epithelial cysts. J Am Soc Nephrol 1993; 3:1843-57.
7. Grantham JJ. Renal cell proliferation and the two faces of cyclic adenosine monophosphate. J Lab Clin Med 1997; 130:459-60.
8. Grantham JJ, Wallace DP. Return of the secretory kidney. Am J Physiol 2002; 282:F1-9.
9. Grantham JJ. Understanding polycystic kidney disease: A systems biology approach. Kidney Int 2003; 64:1157-62.
10. Wallace DP, Grantham JJ, Sullivan LP. Chloride and fluid secretion by cultured human polycystic kidney cells. Kidney Int 1996; 50:1327-36.
11. Davidow CJ, Maser RL, Rome LA, et al. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996; 50:208-18.
12. Schwiebert EM, Wallace DP, Braunstein GM, et al. Autocrine extracellular purinergic signaling in epithelial cells derived from polycystic kidneys. Am J Physiol 2002; 282:F763-75.
13. Torres VE. Cyclic AMP, at the hub of the cystic cycle. Kidney Int 2004; 66:1283-5.
14. Yamaguchi T, Pelling JC, Ramaswamy NT, et al. Cyclic AMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57:1460-71.
15. Yamaguchi T, Nagao S, Wallace DP, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal dominant polycystic kidneys. Kidney Int 2003; 63:1983-94.
16. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006; 17:178-87.
17. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384-98.
18. Ong ACM, Harris PC. Molecular pathogenesis of ADPKD: The polycystin complex gets complex. Kidney Int 2005; 67:1234-47.
19. Torres VE, Harris PC. Mechanisms of Disease: Autosomal dominant and recessive polycystic kidney diseases. Nature Clin Pract Nephrol 2006; 2:40-55.
20. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Nat Acad Sci USA 2006; 103:5466-71.
21. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24.
22. Davenport JR, Yoder BK. An incredible decade for the primary cilium: A look at a once-forgotten organelle. AJP Renal Physiol 2005; 289:1159-69.
23. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002; 13:2508-16.
24. Pazour JG, Dickert BL, Vucica Y, et al. Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene tg737, are required for assembly of cilia and flagella. J Cell Biol 2000; 151:709-18.
25. Lin F, Hiesberger T, Cordes K, et al. Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci USA 2003; 100:5286-91.
26. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33:129-37.
27. Lubarsky B, Krasnow MA. Tube morphogenesis: Making and shaping biological tubes. Cell 2003; 112:19-28.
28. Montesano R, Schaller G, Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 1991; 66:697-711.
29. Pollack AL, Runyan RB, Mostov KE. Morphogenetic mechanisms of epithelial tubulogenesis: MDCK cell polarity is transiently rearranged without loss of cell-cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis. Dev Biol 1998; 204:64-79.
30. O'Brien LE, Zegers MM, Mostov KE. Building epithelial architecture: insights from three-dimensional culture models. Nat Rev Mol Cell Biol 2002; 3:531-7.
31. Schwartz EA, Leonard ML, Bizios R, Bowser SS. Analysis and modelling of the primary cilium bending response to fluid shear. Am J Physiol 1997; 272:F132-8.
32. Calvet JP. Cilia in PKD-Letting it all hang out. J Am Soc Nephrol 2002; 13:2614-16.
33. Dalgaard OZ. Bilateral polycystic disease of the kidneys. Acta Med Scand 1957; 328:1-255.
34. Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, et al. Perinatal lethality with kidney and pancreas defects in mice with a targeted PKD1 mutation. Nat Genet 1997; 17:179-81.
35. Kim K, Drummond I, Ibraghimov-Breskovnaya O, Klinger K, Arnaout MA. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 2000; 97:1731-6.
36. Wu G, Markowitz GS, Li L, D'Agati VD, Factor SM, et al. Cardiac defects and renal failure in mice with targeted mutations in PKD 2. Nat Genet 2000; 24:75-8.
37. Watnick TJ, Torres VE, Gandolph MA, et al. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell 1998; 2:247-51.
38. Brasier JL, Henske EP. Loss of the polycystic disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. J Clin Invest 1997; 99:1-6.
39. Nauli SM, Rosetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, et al. Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol 2006; 17:1015-25.
40. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1:148-57.
41. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Consortium for radiological imaging studies of polycystic kidney disease cohort: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD). The Consortium for radiological imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 2003; 64:2214-21.
42. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354:2122-30.
43. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 2005; 68(Suppl. 99): S57-65.
44. Jafar TH, Stark PC, Schmid CH, Strandgard S, Kamper A-L, Maschio G, Becker G, Perrone R, Levey AS. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67:265-71.
45. Cadnapaphomchai MA, Fick-Brosnahan GM, Duly I, Johnson AM, Strain JD, et al. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adults with autosomal dominant polycystic kidney disease (ADPKD). Contemp Clin Trials 2005; 26:211-22.
46. Martinez-Maldonaldo M, Yium JJ, Eknoyan G, et al. Adult polycystic kidney disease: Studies of the defect in urinary concentration. Kidney Int 1972; 2:107-13.
47. Gabow P, Kaehny W, Johnson AM, et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 1989; 35:675-80.
48. Gattone VH, Maser RL, Tian C, et al. Developmental expression of urine-concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 1999; 24:309-18.
49. Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Med 2003; 9:1323-6.
50. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med 2004; 10:363-4.
51. Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretic versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21:98-103.
52. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int 2005; 68(Suppl. 99):S87-93.
53. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. The mavelonate pathway: Importance in mesangial cell biology and glomerular disease. Miner Electrolyte Metab 1993; 19:173-9.
54. Gile RD, Cowley BD Jr, Gattone VH, O'Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 1995; 26:501-7.
55. Cowley BD, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Clavet JP, Gattone VH. Autosomal polycystic disease in the rat. Kidney Int 1993; 43:522-34.
56. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ. Effect of simvastatin on renal function in autosomal polycystic kidney disease. Nephrol Dial Transplant 2001; 16:2152-7.
57. Cowley BD, Smardo FL, Grantham JJ, Calvet JP. Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease. Proc Natl Acad Sci USA 1988; 85:2578.
58. Harding MA, Gattone VH, Grantham JJ, Calvet JP. Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse. Kidney Int 1992; 41:317-25.
59. Husson H, Manavalan P, Akmaev VR, Russo RJ, Cook B, Richards B, Barberio D, Liu D, Cao X, Landes GM, et al. New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies. Genomics 2004; 84:497-510.
60. Trudel M, D'Agati V, Constantini F. C-myc as an inducer of polycystic disease in transgenic mice. Kidney Int 1991; 39:665-71.
61. Trudel M, Chretien M, D'Agati V. Disappearance of polycystic kidney disease in revertant c-myc transgenic mice. Mamm Genome 1994; 5:149-52.
62. Ricker JL, Mata JE, Iversen PL, Gattone VH. C-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 2002; 61(Suppl. 1):125-31.
63. Ricker JL, Gattone VH, Calvet JP, Rankin CA. Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice. J Am Soc Nephrol 2000; 11:1837-47.
64. Gattone VH. Emerging therapies for polycystic kidney disease. Curr Opinion Pharm 2005; 5:535-42.
65. Gattone VH, Ricker JL, Trambaugh CM, Klein RM. Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney disease. Kidney Int 2002; 62:1560-9.
66. Gattone VH, Andrews GK, Niu FW, Chadwick LJ, Klein RM. Defective epidermal growth factor gene expression in mice with polycystic kidney disease. Develop Biol 1990; 138:225-30.
67. Cowley BJ, Rupp J. Abnormal expression of epidermal growth factor and sulfated glycoprotein SGP-2 messenger RNA in a rat model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 6:1679-81.
68. Weinstein T, Hwang D, Lev-Ran A, Ori Y, Korzets A, Levi J. Excretion of epidermal growth factor in human adult polycystic kidney disease. Isr J Med Sci 1997; 33:641-2.
69. Orellana SA, Sweeney WE, Neff CD, Avner ED. Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney Int 1995; 47:490-9.
70. Sweeney WE, Avner ED. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease. Am J Physiol 1998; 275:F387-94.
71. Nauta J, Sweeney WE, Rutledge JC, Avner ED. Biliary epithelial cells from mice with congenital polycystic kidney disease are hyperresponsive to epidermal growth factor. Pediatr Res 1995; 37:755-63.
72. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 2000; 57:33-40.
73. Torres VE, Sweeney WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003; 64:1573-9.
74. Torres VE, Sweeney WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED. EGF receptor tyrosine kinase inhibition is not effective in PCK rats. Kidney Int 2004; 66:1766-73.
75. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Med 2005; 16:46-51.
76. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic disease (ADPKD). Nephrol Dial Transplant 2006; 21:598-604.
77. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68:206-16.
78. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287:860-7.